dsm-firmenich Pharma Solutions

The pharmaceutical industry is under increasing pressure to develop more patient-friendly dosage forms. The rise of pill fatigue—especially in chronic disease management—and conditions like dysphagia have significantly impacted patient compliance. On top of that, over 60% of APIs are considered to be bitter, making #taste a key factor in adherence and supporting better treatment outcomes. To help drug developers overcome taste challenges, our whitepaper explores due diligence considerations and science-backed solutions from #flavor tonalities to taste modulation technologies, sensates, and encapsulation techniques. Unlock the insights that can drive your success! https://bit.ly/4j7lkPV #TogetherElevatingHealth #WeBringProgressToLife #dsmfirmenichPharma #Pharmaceuticals

Your mission is to bring life-changing and life-saving medicines to market. Ours is to help you achieve this with confidence. Introducing our API portfolio elevated by Verilege™, a suite of expert services and superior customer care, ready to help you enter, navigate, and expand within the pharmaceutical market with confidence. Discover how Verilege™ delivers the quality, regulatory, and sustainability services you need to succeed. Learn more: https://bit.ly/4iNq8dK #TogetherElevatingHealth #WeBringProgressToLife #dsmfirmenichPharma #Pharmaceuticals #DrugDevelopment

CBtru®, our first-in-class #cannabidiol drug product intermediate, delivers high drug loading and optimized bioavailability—paving the way for tablets, capsules, and other oral solid dosage forms in the cannabidiol market. At the recent UIC Australian Medical Cannabis Symposium, dsm-firmenich expert, Athanasia Kanli, presented exciting findings from our first human clinical trial comparing CBtru® to the current gold standard liquid oil-based cannabidiol drug product on the market. The key takeaways? CBtru® demonstrates: ✅ Comparable bioavailability in fed state (with a high fat meal) ✅ Higher bioavailability in fasted state ✅ More reliable and consistent uptake, possibly less dependent on food intake Explore the data in more detail with Athanasia Kanli—access to her presentation here: https://bit.ly/41Immet #TogetherElevatingHealth #WeBringProgressToLife #dsmfirmenichPharma #Pharmaceuticals #Cannabinoids #DrugDevelopment

How can we improve the #taste of bitter medicines to enhance patient experience? Improving the palatability of medications can enhance treatment adherence and, ultimately, lead to better therapeutic outcomes. In our new whitepaper we explore how drug developers can elevate patient compliance with innovative #flavor tonalities and taste modulation solutions. ● Understand when in the drug development process is the right time to talk taste ● Discover how to tailor flavor solutions to specific active ingredients ● Meet the preferences of different patient demographics ● Explore key considerations like efficacy, safety, and compliance 👉🏻 Get your copy today! https://bit.ly/4hRLcyw #TogetherElevatingHealth #WeBringProgressToLife #dsmfirmenichPharma #Pharmaceuticals

Last month at the UIC Australian Medical Cannabis Symposium, Athanasia Kanli, our Senior Director, Global Marketing and Business Development for Pharma, shared promising results from our first human clinical trial using CBtru®, an innovative formulated #cannabidiol drug product intermediate with enhanced bioavailability. 🎤 “The results show that the plasma concentration of cannabidiol 24 hours after a single administration of CBtru® was equivalent to the current gold standard liquid, oil-based cannabidiol drug product in fed state (with a high fat meal) and higher in fasting state,” Athanasia Kanli confirms. Interested to learn how this new scientific development could pave the way for a new era of patient-friendly cannabidiol-based therapies? Watch the expert talk on demand: https://bit.ly/41DwQvA #TogetherElevatingHealth #WeBringProgressToLife #dsmfirmenichPharma #Pharmaceuticals #Cannabinoids #DrugDevelopment

#DCATWeek is where innovation and opportunity meet! Our team has an incredible time at DCAT Week 2025, where we connect with industry leaders, customers, and partners. This event is always a valuable opportunity to engage in strategic meetings and innovation dialogues, helping us strengthen existing relationships and explore new ways to bring progress to live in the pharmaceutical industry. A huge thank you to everyone who joined us at this amazing event! We look forward to continuing the discussions and to together elevating patient health. #InspiredByPatientsDeliveredByExperts #TogetherElevatingHealth #WeBringProgressToLife #TasteSolutions #Cannabidiol #DrugDevelopment Kelsey Achenbach Fernanda Onofre Mary Ellen Johnson Thomas Sobik Julia Duchastel de Montrouge Sylvain Diguet

A breakthrough clinical study has confirmed that our #cannabidiol drug product intermediate, CBtru®, has the potential to unlock more patient-friendly oral solid dosage forms in the cannabidiol space—a true gamechanger in this growing category! The trial demonstrated that CBtru® can help overcome a common barrier to developing solid dosage forms—limited bioavailability. The study findings validate that the bioavailability of CBtru® is as good as the current leading cannabidiol-based drug on the market, which is a liquid oil-based product. Discover four key takeaways from the study in our new blog, and find out what this means for patients and the industry: https://bit.ly/43pAXh5 #TogetherElevatingHealth #WeBringProgressToLife #dsmfirmenichPharma #Pharmaceuticals #Cannabinoids #DrugDevelopment

👉 Thrilled to announce that our colleague Guy Servant, Head of Receptor-Based Discovery, Taste and Health, will be participating in an upcoming expert panel at INTERPHEX Global discussing a common challenge in pharmaceuticals: the bitter taste of APIs. ⚕️ Many widely used medications, especially those requiring frequent or repeated oral dosing, may be difficult to take due to their unpleasant taste. This issue is especially troublesome for super-bitter drugs, where traditional taste-masking methods like coating, microencapsulation, or flavoring may no longer work. 💡 Treatment success for oral delivery of super-bitter drugs depends on novel technologies that allow drug release and absorption without impacting bioavailability. The panel will discuss perspectives from experts working at flavor, excipient, and service providers to address taste-masking for such drugs. Join us at INTERPHEX and register today! https://lnkd.in/g3WKXfbK #PharmaInnovation #TasteMasking #OralDelivery #Pharmaceuticals #PatientCare #DrugDevelopment

What’s on the agenda from dsm-firmenich at #DCATWeek 2025? The launch of a comprehensive #taste offering carefully curated for pharma. The new portfolio supports our customers with the formulation of innovative and palatable drug products, as well as helping them navigate ever-evolving regulatory complexities with confidence. Connect with our team at DCAT Week to find out how the pharma-specific portfolio of #taste solutions can help you stay compliant so that you can focus on what’s important - elevating palatability and patient adherence. 📅 Schedule a meeting with your dedicated dsm-firmenich Account Manager or connect with Julia Duchastel de Montrouge, Segment Lead Pharma, North America at dsm-firmenich, via julia.duchastel@dsm-firmenich.com. #TogetherElevatingHealth #WeBringProgressToLife #dsmfirmenichPharma #DCAT #Pharmaceuticals

Cannabidiol has been gaining attention in the pharmaceutical landscape thanks to its promising therapeutic potential in a range of conditions, including neurological disorders, mood disorders, cancers, chronic pain, and even sleep disorders. However, its bioavailability in humans is limited, which has restricted its application in oral solid dosage forms—until now. 🔬 New research validates CBtru®, a first-to-market cannabidiol drug product intermediate, as a compelling pathway for more patient-friendly cannabidiol-based therapies. Results from the clinical trial revealed that in fed state, the bioavailability of CBtru® is as good as that of the only commercially approved cannabidiol-based drug product, which is a liquid oil-based dosage form. And in fasted state, CBtru® demonstrated even higher bioavailability than the approved drug. Explore how these findings will open doors to more patient-friendly therapies in our new blog: https://bit.ly/43zvsfM #TogetherElevatingHealth #WeBringProgressToLife #dsmfirmenichPharma #Pharmaceuticals #Cannabinoids #DrugDevelopment